A5087797414- Ophthalmology and Eye Disorders
- Thyroid Disorders and Treatments
- Pituitary Gland Disorders and Treatments
- Glaucoma and retinal disorders
- Diabetes and associated disorders
- Thyroid Cancer Diagnosis and Treatment
- Adrenal Hormones and Disorders
- Growth Hormone and Insulin-like Growth Factors
- Advanced Differential Geometry Research
- Ocular Surface and Contact Lens
- Erythrocyte Function and Pathophysiology
- Monoclonal and Polyclonal Antibodies Research
- Ion channel regulation and function
- Child Abuse and Related Trauma
- T-cell and B-cell Immunology
- Blood disorders and treatments
- Hormonal Regulation and Hypertension
- Cerebral Venous Sinus Thrombosis
- Celiac Disease Research and Management
- Blood groups and transfusion
- Neuroendocrine Tumor Research Advances
- Immunodeficiency and Autoimmune Disorders
- Microscopic Colitis
- Vestibular and auditory disorders
- Sympathectomy and Hyperhidrosis Treatments
Johannes Gutenberg University Mainz
2016-2025
University Medical Center of the Johannes Gutenberg University Mainz
2016-2025
University of Chicago
2023
Walter de Gruyter (Germany)
2022
Azienda Ospedaliera di Padova
2022
University of Padua
2022
University of Applied Sciences Mainz
2021
University of Insubria
2021
Technische Universität Dresden
2021
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie
1998-2020
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of disease, though severe forms are rare. Management GO often suboptimal, largely because available treatments do not target pathogenic mechanisms disease. Treatment should rely on a thorough assessment activity and severity its impact patient's quality life. Local measures (artificial tears, ointments dark glasses) control risk factors for progression (smoking thyroid dysfunction) recommended all patients. In mild GO,...
Summary of consensus a. All patients with GO should (Fig. 1):Be referred to specialist centers;Be encouraged quit smoking;Receive prompt treatment in order restore andmaintain euthyroidism.b. Patients sight-threatening be treatedwith i.v. GCs as the first-line treatment; if responseis poor after 1–2 weeks, they submitted tourgent surgical decompression.c. The choice for moderate-to-severe isi.v. (with or without OR) orbitopathy isactive;surgery(orbitaldecompression,squintsurgery,and/or eyelid...
Graves' disease (GD) is a systemic autoimmune disorder characterized by the infiltration of thyroid antigen-specific T cells into thyroid-stimulating hormone receptor (TSH-R)-expressing tissues. Stimulatory autoantibodies (Ab) in GD activate TSH-R leading to hyperplasia and unregulated production secretion. Diagnosis straightforward patient with biochemically confirmed thyrotoxicosis, positive TSH-R-Ab, hypervascular hypoechoic gland (ultrasound), associated orbitopathy. In GD, measurement...
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of disease (GD). Choice treatment should be based on assessment clinical activity and severity GO. Early referral to specialized centers fundamental for most patients with Risk factors include smoking, thyroid dysfunction, high serum level thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, hypercholesterolemia. In mild active GO, control risk factors, local treatments, selenium (selenium-deficient areas) are...
Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition the insulin-like growth factor I receptor (IGF-IR) is new therapeutic strategy to attenuate underlying autoimmune pathogenesis ophthalmopathy.
We carried out a randomized, double-blind, placebo-controlled trial to determine the effect of selenium (an antioxidant agent) or pentoxifylline antiinflammatory in 159 patients with mild Graves' orbitopathy. The were given sodium selenite (100 μg twice daily), (600 mg placebo (twice daily) orally for 6 months and then followed after treatment was withdrawn. Primary outcomes at evaluated by means an overall ophthalmic assessment, conducted ophthalmologist who unaware assignments,...
Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food Drug Administration-approved medical therapy available. Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in pathogenesis of this disease.In randomized, double-masked, placebo-controlled, phase 3 multicenter trial, we assigned patients with active thyroid 1:1 ratio to receive intravenous infusions IGF-IR inhibitor teprotumumab (10 mg per kilogram...
Glucocorticoids are effective for severe Graves' orbitopathy (GO), which causes substantial morbidity. The question at issue is how best to use them.The objective of this study was optimize glucocorticoid application in GO.The design a randomized trial over 12 wk with 6-month follow-up.The performed university joint thyroid and ophthalmic clinics.Seventy euthyroid out-patients untreated, active, GO were studied.Patients received either once weekly iv methylprednisolone (0.5 g, then 0.25 6...
Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given controversies regarding treatment of Endo SHyper, formed task force to develop clinical practice guidelines principles...
To evaluate teprotumumab safety/efficacy in patients with thyroid eye disease (TED) who were nonresponsive or experienced a flare.The Treatment of Graves' Orbitopathy to Reduce Proptosis Teprotumumab Infusions an Open-Label Clinical Extension Study (OPTIC-X) is treatment and re-treatment trial following the placebo-controlled Phase 3 (Thyroid Eye Disease) Randomized, Placebo-Controlled, (OPTIC) trial.Patients previously received placebo (n = 37) 14) OPTIC.OPTIC nonresponders those flared...
Polyglandular autoimmune syndromes (PAS) are rare polyendocrinopathies characterized by the failure of several endocrine glands as well nonendocrine organs, caused an immune-mediated destruction tissues. This article summarizes extensive clinical, epidemiological, serological, and genetic data a large collective patients with PAS (n = 360). Since 1988, more than 15,000 adult diseases have been screened at center Mainz University, 151 360 regularly followed. Type 1 diabetes, Graves' disease,...
<b>Background:</b> This study was performed to determine clinical features of dysthyroid optic neuropathy (DON) across Europe. <b>Methods:</b> Forty seven patients with DON presented European centres during one year. Local protocols for thyroid status, ophthalmic examination and further investigation were used. Each eye classified as having definite, equivocal, or no DON. <b>Results:</b> Graves’ hyperthyroidism occurred in the majority; 20% had received radioiodine. Of 94 eyes, 55 definite...
Although the pathomechanisms of autoimmune diseases in various organs remain unresolved, an accumulation individual patients has been observed. An overlap hepatitis (AIH) and primary biliary cirrhosis (PBC) or sclerosing well documented. However, other than PBC PSC not yet investigated a large cohort.The goal our analysis was to investigate incidence concurrent with AIH.We analyzed cohort 278 AIH for diseases.A total 111 (40%) were diagnosed additional diseases. Besides syndromes PSC,...